Acid-suppressive agents and survival outcomes in patients with cancer: a systematic review and meta-analysis
- PDF / 3,683,067 Bytes
- 17 Pages / 595.276 x 790.866 pts Page_size
- 119 Downloads / 218 Views
ORIGINAL ARTICLE
Acid‑suppressive agents and survival outcomes in patients with cancer: a systematic review and meta‑analysis Hyun Jin Song1,2 · Kiyon Rhew3 · Yoon Jae Lee4 · In‑Hyuk Ha4 Received: 26 May 2020 / Accepted: 22 September 2020 © Japan Society of Clinical Oncology 2020
Abstract Background Patients with cancer often receive acid-suppressive agents (ASAs) to treat common gastroesophageal reflux and peptic ulcer diseases. Our systematic review addresses the association between ASAs and survival outcomes in these patients. Methods We searched MEDLINE, EMBASE, and Cochrane until December 2019, including randomized controlled trials (RCTs), quasi-RCTs, and observational studies concerning ASAs that reported progression-free survival (PFS) and/or overall survival (OS). We estimated hazard ratios (HRs) with 95% confidence intervals (CIs) using the random-effects model, and assessed heterogeneity with I2 statistic. Results We included 45,626 patients from 7 RCTs and 18 observational studies, including esophageal/gastric, colorectal, pancreatic, lung, breast, prostate, kidney, and other cancers. Five studies showed that ASAs in lung cancer patients received tyrosine kinase inhibitors (TKIs) had significantly worse PFS (HR 1.64, 95% CI 1.14 − 2.37, I2 = 57%) and OS (HR 1.13, 95% CI 1.05 − 1.21, I2 = 0%) than nonusers. Each of five studies found no significant association between ASAs and OS in esophageal/gastric (HR 0.91, 95% CI 0.77 − 1.09, I2 = 32%) or colorectal cancer patients (HR 1.33, 95% CI 0.96− 1.85, I2 = 0%). ASAs were not significantly associated with an OS in patients with kidney cancer (HR 1.04, 95% CI 0.96 − 1.13, I2 = 28%). Conclusions Meta-analysis showed that ASAs significantly associated with an increased mortality risk in lung cancer patients treated TKIs, but not in patients with esophageal/gastric, colorectal, or kidney cancer. Until further studies confirm these results, caution should be used when administering ASAs and TKIs to patients with lung cancer. Keywords Cancer · Acid-suppressive agent · Survival · Mortality · Proton pump inhibitors · Histamine-2 receptor antagonists
Introduction Hyun Jin Song and Kiyon Rhew contributed equally to this work as the first authors. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10147-020-01795-7) contains supplementary material, which is available to authorized users. * Hyun Jin Song [email protected] 1
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea
2
Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, HPNP Building Room 2320, 1225 Center Drive, Gainesville, FL 32610, USA
3
College of Pharmacy, Dongduk Women’s University, Seoul, South Korea
4
Jaseng Spine and Joint Research Institute, Jaseng Medical Foundation, Seoul, South Korea
Acid-suppressive agents (ASAs), proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs), are mainly used to treat gastroesophageal reflux disease (GERD) and peptic ul
Data Loading...
